Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NASDAQ: NBTX) provided a progress update and financial results for 2022, emphasizing advancements in its clinical trials and R&D focus. The ongoing Phase 3 trial, NANORAY-312, is operational in 104 sites across 25 countries, with interim efficacy analysis expected in H2 2024. Financially, the company reported a net loss of €57 million, up from €47 million in 2021, with cash and cash equivalents at €41.4 million as of December 31, 2022. The company anticipates its current cash will suffice until Q3 2023, but cautioned about ongoing risks regarding its going concern status due to substantial operating losses. Key upcoming milestones include final data from Study 102 and pancreatic cancer data from MD Anderson, both expected in H2 2023, while a new Chief Medical Officer is anticipated in Q3 2023.

Nanobiotix (NASDAQ: NBTX) announces it will release its full-year financial results for 2022 on April 24, 2023, after the US market closes. A conference call is scheduled for April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, where CEO Laurent Levy and CFO Bart van Rhijn will discuss year-end results and current business activities. The company is focused on physics-based therapeutic approaches in oncology and has achieved market authorization for its lead product, NBTXR3, in Europe for treating soft tissue sarcoma. Founded in 2003 and headquartered in Paris, Nanobiotix is publicly traded on Euronext and NASDAQ, reflecting its commitment to innovative cancer treatments.

Nanobiotix announced on April 11, 2023, its monthly update regarding the total number of voting rights and shares outstanding. For March 31, 2023, the company reported 34,875,872 shares outstanding and 36,634,849 total voting rights, with 36,612,731 of them exercisable. This disclosure complies with French regulations aimed at ensuring transparency in public companies. Nanobiotix is engaged in pioneering therapeutic approaches for treating solid tumors, notably through its lead product, NBTXR3, targeting head and neck cancers. Further information about the company and its innovations can be found on their official website.

Nanobiotix (NASDAQ: NBTX), a clinical biotechnology company focused on cancer treatment, has announced a postponement of its full-year 2022 financial results originally set for March 28, 2023, and its conference call on March 29, 2023. The decision is made to provide additional time for year-end closing procedures. The company will issue a future press release to update stakeholders on the new schedule. Nanobiotix is recognized for its innovative physics-based therapeutic approaches and has developed NBTXR3, which has received market approval in Europe for treating soft tissue sarcoma.

Nanobiotix, a late-stage clinical biotechnology company, will provide an operational update and financial results for the fiscal year ending December 31, 2022, on March 28, 2023. A conference call will follow on March 29, 2023, at 2:00 PM CET/8:00 AM EDT, led by CEO Laurent Levy and CFO Bart Van Rhijn. The focus will be on year-end results and business updates. Nanobiotix's lead product, NBTXR3, a potential first-in-class oncology treatment, is being evaluated for locally advanced head and neck cancer with favorable early-phase data. The company has strategic collaborations to expand product development across tumor types.

Nanobiotix has released its latest update on the total number of voting rights and shares as of January 31, 2023. The total number of shares outstanding is 34,875,872, with 36,286,976 theoretical voting rights and 36,264,858 exercisable voting rights. This report aligns with the French Commercial Code requirements for transparency. Nanobiotix's lead product candidate, NBTXR3, aims to enhance treatment outcomes for solid tumors, particularly in head and neck cancers. For further details, visit their website at www.nanobiotix.com.

Nanobiotix disclosed key shareholder information as of December 31, 2022. The total number of shares outstanding was 34,875,872, while total voting rights were 36,287,449 (theoretical) and 36,265,331 (exercisable). The company announced the termination of its liquidity contract with Gilbert Dupont, effective December 20, 2022. This follows a prior announcement on December 21, 2022. Going forward, Nanobiotix will provide monthly updates on voting rights and shares as required by French regulations.